AbbVie is increasing Humira's price by 9.7%. That price increase could add $1.2 billion to the US healthcare system’s drug costs in 2018, according to one analyst.
Even though many of the drug price increases announced in recent days have generally remained below 10%—the self-imposed cap that some companies appear to have adopted—these increases will still cost payers and patients a great deal, particularly in the case of Humira (adalimumab), the blockbuster rheumatoid arthritis (RA)/inflammatory disease treatment, the price of which manufacturer AbbVie is increasing by 9.7%. That single price increase could add $1.2 billion to the US healthcare system’s drug costs in 2018, according to Wells Fargo analyst David Maris.
“AbbVie's 9.7% increase is likely to be the costliest price hike to the U.S. healthcare system,” Maris said. “With the drug bringing in $12.6 billion in the [United States] each year, that price increase means an added $1.2 billion to the healthcare system." Over the past 5 years, Humira’s price has more than doubled, thanks to incremental hikes, Maris noted. Humira is now the best-selling drug in the world, expected to earn $20 billion or more worldwide—the first drug to ever pass that threshold.
And there’s no immediate biosimilar competition for Humira in the United States after AbbVie successfully delayed biosimilar competition from Amgen, which received FDA approval in September 2016 for its adalimumab biosimilar (Amjevita). (The European Commission also approved Amgen’s adalimumab biosimilar in March 2017.) Patent disputes delayed the launch of the biosimilar, with AbbVie suing Amgen for infringing on 10 its patents. Amgen reached a settlement with AbbVie in September 2017 under which AbbVie will grant patent licenses to Amgen for the sale of Amjevita on a country-by-country basis, and the companies have dismissed all pending litigation over the drug. In addition, Amgen will launch its biosimilar in the European Union (under the name Amgevita) on October 16, 2018, but in the United States, Amjevita will not launch until January 31, 2023. Boehringer Ingelheim’s adalimumab biosimilar (Cyltezo) was also approved by the FDA in August 2017, but is the subject of additional patent litigation.
Humira continues to dominate the RA and inflammatory disease markets despite an assessment by the Institute for Clinical and Economic Review (ICER), an independent cost-effectiveness watchdog, which concluded that Humira isn’t worth its current price and doesn’t work as well as 2 of its competitors. ICER stated that, to be cost-effective, Humira’s net price would need to be at a 50% to 69% discount to its list price at the time of the assessment.
The organization concluded that targeted immune-modulating RA drugs (TIMs), like Humira, work better than older treatments such as methotrexate, but the prices of TIMs detracted from their cost-effectiveness rating, which ICER bases on a quality-adjusted life-year (QALY) analysis. Most immune modulators exceed traditional cost-QALY analysis thresholds, according to ICER. In fact, Humira has the highest per-QALY cost of the all anti—tumor necrosis factor drugs at $232,664. Infliximab (Remicade) had the lowest at $202,824. While biosimilar competition for adalimumab is delayed potential competition for Humira may eventually come in the form of novel drugs that are expected to erode its dominance in the RA market, such as Janus kinase inhibitors.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.